EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID ‐19

Abdullah F Alharthi iD, Munirah A Alkathiri, Othman Alomeir, Shmeylan Al Harbi, Ohoud Aljuhani, Haifa A Alhaidal, Khalid Al Sulaiman

Clinical Case Reports · 2026-11 · 14 (11)

DOI: 10.1002/ccr3.73787 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 30.10.2026. Verfasst von Abdullah F Alharthi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy Shaqra University Al-Dawadmi Saudi Arabia. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug‐induced thrombocytopenia is a condition where certain medications can significantly reduce the platelets in the blood. This can increase the risk of bleeding and bruising. We reported a case of a 73‐year‐old woman with multiple comorbidities who was admitted to the hospital with COVID‐19. Upon admission, the patient received multiple antibiotics, including Piperacillin/Tazobactam. In the following days, she developed severe thrombocytopenia upon re‐exposure to Piperacillin/Tazobactam. Other causes of thrombocytopenia were systematically excluded. After discontinuing the Piperacillin/Tazobactam and administering intravenous immunoglobulin (IVIG), the thrombocytopenia resolved. A Naranjo Adverse Drug Reaction Probability Scale score was calculated and indicated a probable (i.e., 6 points) adverse drug reaction. This case underscores the importance of considering Piperacillin/Tazobactam as a potential cause of severe thrombocytopenia in critically ill patients, even in the presence of confounding factors such as COVID‐19. To our knowledge, this is a rarely reported presentation in a patient with a recent COVID‐19 infection. Further studies are needed to clarify the relationship between COVID‐19 and drug‐induced thrombocytopenia.

Schlagwörter

Stichwörter der Autor:innen

COVID‐19case reportcritically illdrug‐induced thrombocytopeniapiperacillin/tazobactam

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, College of Pharmacy Shaqra University Al-Dawadmi Saudi Arabia.
  • Pharmaceutical Care Division King Faisal Specialist Hospital and Research Centre Riyadh Saudi Arabia.
  • Pharmaceutical Care Department King Abdulaziz Medical City Riyadh Saudi Arabia.
  • College of Pharmacy King Saud Bin Abdulaziz University for Health Sciences Riyadh Saudi Arabia.
  • Clinical Trial Management King Abdullah International Medical Research Center Riyadh Saudi Arabia.
  • Department of Pharmacy Practice, Faculty of Pharmacy King Abdulaziz University Jeddah Saudi Arabia.

ORCID-Profile: Abdullah F Alharthi

Zitieren

APA

Alharthi, A. F., Alkathiri, M. A., Alomeir, O., Al Harbi, S., Aljuhani, O., Alhaidal, H. A., & Al Sulaiman, K. (2026). Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID ‐19. Clinical Case Reports, 14(11). https://doi.org/10.1002/ccr3.73787

Vancouver

Alharthi AF, Alkathiri MA, Alomeir O, Al Harbi S, Aljuhani O, Alhaidal HA, et al. Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID ‐19. Clinical Case Reports. 2026;14(11). doi:10.1002/ccr3.73787

BibTeX
@article{Alharthi2026,
  author = {Alharthi, Abdullah F and Alkathiri, Munirah A and Alomeir, Othman and Al Harbi, Shmeylan and Aljuhani, Ohoud and Alhaidal, Haifa A and Al Sulaiman, Khalid},
  title = {Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID ‐19},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1002/ccr3.73787}
}
Kostenlos starten →